As of 14 Oct 2026, Alveus Therapeutics has raised $160M across 1 verified round on record; latest: $160 million Series A led by Andera Partners, New Rhein Healthcare Investors and 1 other, announced 8 Jan 2026.
Alveustx specializes in developing next-generation treatments for obesity and metabolic diseases.
1 source
The article says "about $160 million"; the amount is reported as $160 million, while the headline abbreviates it as $160M.
Published by hand (biopharmadive.com): "Alveus launches with $160M to advance MariTide-like obesity drug": hand-checked (K, non-US): the page states the company, the equity amount and the day
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $160M | 2026-01-08 | Andera Partners, New Rhein Healthcare Investors, Omega Funds | No recent discussion |
1 source [ VERIFIED · CORRECTED ] read against 1 source
The article says "about $160 million"; the amount is reported as $160 million, while the headline abbreviates it as $160M. Published by hand (biopharmadive.com): "Alveus launches with $160M to advance MariTide-like obesity drug": hand-checked (K, non-US): the page states the company, the equity amount and the day [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: biopharmadive.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage | ||||